72 related articles for article (PubMed ID: 18242509)
21. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication.
Nakayama K; Nagahama H; Minamishima YA; Matsumoto M; Nakamichi I; Kitagawa K; Shirane M; Tsunematsu R; Tsukiyama T; Ishida N; Kitagawa M; Nakayama K; Hatakeyama S
EMBO J; 2000 May; 19(9):2069-81. PubMed ID: 10790373
[TBL] [Abstract][Full Text] [Related]
22. Skp2 regulates the antiproliferative function of the tumor suppressor RASSF1A via ubiquitin-mediated degradation at the G1-S transition.
Song MS; Song SJ; Kim SJ; Nakayama K; Nakayama KI; Lim DS
Oncogene; 2008 May; 27(22):3176-85. PubMed ID: 18071316
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer.
Hershko DD
Cancer; 2008 Apr; 112(7):1415-24. PubMed ID: 18260093
[TBL] [Abstract][Full Text] [Related]
24. Skp2 is oncogenic and overexpressed in human cancers.
Gstaiger M; Jordan R; Lim M; Catzavelos C; Mestan J; Slingerland J; Krek W
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5043-8. PubMed ID: 11309491
[TBL] [Abstract][Full Text] [Related]
25. SKP2 promotes breast cancer tumorigenesis and radiation tolerance through PDCD4 ubiquitination.
Li C; Du L; Ren Y; Liu X; Jiao Q; Cui D; Wen M; Wang C; Wei G; Wang Y; Ji A; Wang Q
J Exp Clin Cancer Res; 2019 Feb; 38(1):76. PubMed ID: 30760284
[TBL] [Abstract][Full Text] [Related]
26. Polyubiquitination of p53 by a ubiquitin ligase activity of p300.
Grossman SR; Deato ME; Brignone C; Chan HM; Kung AL; Tagami H; Nakatani Y; Livingston DM
Science; 2003 Apr; 300(5617):342-4. PubMed ID: 12690203
[TBL] [Abstract][Full Text] [Related]
27. Foxo3a transcription factor is a negative regulator of Skp2 and Skp2 SCF complex.
Wu J; Lee SW; Zhang X; Han F; Kwan SY; Yuan X; Yang WL; Jeong YS; Rezaeian AH; Gao Y; Zeng YX; Lin HK
Oncogene; 2013 Jan; 32(1):78-85. PubMed ID: 22310285
[TBL] [Abstract][Full Text] [Related]
28. STAT1 represses Skp2 gene transcription to promote p27Kip1 stabilization in Ras-transformed cells.
Wang S; Raven JF; Koromilas AE
Mol Cancer Res; 2010 May; 8(5):798-805. PubMed ID: 20407011
[TBL] [Abstract][Full Text] [Related]
29. EGCG stabilizes p27kip1 in E2-stimulated MCF-7 cells through down-regulation of the Skp2 protein.
Huang HC; Way TD; Lin CL; Lin JK
Endocrinology; 2008 Dec; 149(12):5972-83. PubMed ID: 18719023
[TBL] [Abstract][Full Text] [Related]
30. RNA silencing of S-phase kinase-interacting protein 2 inhibits proliferation and centrosome amplification in lung cancer cells.
Jiang F; Caraway NP; Li R; Katz RL
Oncogene; 2005 May; 24(21):3409-18. PubMed ID: 15735730
[TBL] [Abstract][Full Text] [Related]
31. Modification of the p53 transgene of a replication-competent adenovirus prevents mdm2- and E1b-55kD-mediated degradation of p53.
Sauthoff H; Pipiya T; Chen S; Heitner S; Cheng J; Huang YQ; Rom WN; Hay JG
Cancer Gene Ther; 2006 Jul; 13(7):686-95. PubMed ID: 16470212
[TBL] [Abstract][Full Text] [Related]
32. Mdm2-mediated pRB downregulation is involved in carcinogenesis in a p53-independent manner.
Miwa S; Uchida C; Kitagawa K; Hattori T; Oda T; Sugimura H; Yasuda H; Nakamura H; Chida K; Kitagawa M
Biochem Biophys Res Commun; 2006 Feb; 340(1):54-61. PubMed ID: 16343421
[TBL] [Abstract][Full Text] [Related]
33. Degradation of Tob1 mediated by SCFSkp2-dependent ubiquitination.
Hiramatsu Y; Kitagawa K; Suzuki T; Uchida C; Hattori T; Kikuchi H; Oda T; Hatakeyama S; Nakayama KI; Yamamoto T; Konno H; Kitagawa M
Cancer Res; 2006 Sep; 66(17):8477-83. PubMed ID: 16951159
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of cell-cycle control: ligating the ligase.
Lin DI; Diehl JA
Trends Biochem Sci; 2004 Sep; 29(9):453-5. PubMed ID: 15337116
[TBL] [Abstract][Full Text] [Related]
35. Notch signaling induces SKP2 expression and promotes reduction of p27Kip1 in T-cell acute lymphoblastic leukemia cell lines.
Dohda T; Maljukova A; Liu L; Heyman M; Grandér D; Brodin D; Sangfelt O; Lendahl U
Exp Cell Res; 2007 Aug; 313(14):3141-52. PubMed ID: 17560996
[TBL] [Abstract][Full Text] [Related]
36. E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy.
Hao Z; Huang S
Front Biosci (Landmark Ed); 2015 Jan; 20(3):474-90. PubMed ID: 25553462
[TBL] [Abstract][Full Text] [Related]
37. Skp2 and p27kip1 expression in melanocytic nevi and melanoma: an inverse relationship.
Li Q; Murphy M; Ross J; Sheehan C; Carlson JA
J Cutan Pathol; 2004 Nov; 31(10):633-42. PubMed ID: 15491322
[TBL] [Abstract][Full Text] [Related]
38. Skp2B attenuates p53 function by inhibiting prohibitin.
Chander H; Halpern M; Resnick-Silverman L; Manfredi JJ; Germain D
EMBO Rep; 2010 Mar; 11(3):220-5. PubMed ID: 20134482
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.
Chan CH; Morrow JK; Li CF; Gao Y; Jin G; Moten A; Stagg LJ; Ladbury JE; Cai Z; Xu D; Logothetis CJ; Hung MC; Zhang S; Lin HK
Cell; 2013 Aug; 154(3):556-68. PubMed ID: 23911321
[TBL] [Abstract][Full Text] [Related]
40. SKP2 Knockout in Rb1/p53-Deficient Mouse Models of Osteosarcoma Induces Immune Infiltration and Drives a Transcriptional Program with a Favorable Prognosis.
Ferrena A; Wang J; Zhang R; Karadal-Ferrena B; Al-Hardan W; Singh S; Borjihan H; Schwartz EL; Zhao H; Oktay MH; Yang R; Geller DS; Hoang BH; Zheng D
Mol Cancer Ther; 2024 Feb; 23(2):223-234. PubMed ID: 37871911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
